

# Zefen Xiao

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4449712/zefen-xiao-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74 papers	902 citations	17 h-index	27 g-index
82 ext. papers	1,206 ext. citations	3.8 avg, IF	3.57 L-index

#	Paper	IF	Citations
74	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.. <i>Clinical Medicine Insights: Oncology</i> , <b>2022</b> , 16, 11795549221080347	1.8	0
73	Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution.. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 1	3.1	1
72	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma.. <i>Radiation Oncology</i> , <b>2022</b> , 17, 58	4.2	
71	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 781340	5.3	0
70	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211061948	5.4	0
69	Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. <i>Tumori</i> , <b>2021</b> , 107, 407-415	1.7	0
68	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 156, 244-250	5.3	3
67	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. <i>Acta Oncologica</i> , <b>2021</b> , 60, 627-634	3.2	4
66	Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 7076-7084	3.1	0
65	Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1831-1840	3.2	1
64	Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 618776	5.3	
63	Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China. <i>Radiation Oncology</i> , <b>2021</b> , 16, 102	4.2	2
62	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. <i>Lung Cancer</i> , <b>2021</b> , 157, 116-123	5.9	1
61	RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. <i>Future Oncology</i> , <b>2021</b> , 17, 4081-4089	3.6	2
60	Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A).. <i>Translational Cancer Research</i> , <b>2021</b> , 10, 2932-2943	0.3	0
59	Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. <i>Oncologist</i> , <b>2021</b> , 26, e2151-e2160	5.7	1
58	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1178-1185	13.4	23

57	Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 814-823	3.2	4
56	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.. <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	2
55	Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. <i>BMC Cancer</i> , <b>2020</b> , 20, 144	4.8	8
54	A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma. <i>BMC Cancer</i> , <b>2020</b> , 20, 130	4.8	5
53	Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. <i>Oncologist</i> , <b>2020</b> , 25, e701-e708	5.7	11
52	Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A). <i>BMC Cancer</i> , <b>2020</b> , 20, 36	4.8	7
51	A phase III trial in progress comparing tislelizumab plus concurrent chemoradiotherapy (cCRT) with placebo plus cCRT in patients with localized esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS475-TPS475	2.2	
50	Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03). <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 1140	3.2	1
49	Stage III Esophageal Squamous Cell Carcinoma Patients With Three-Dimensional Conformal or Intensity-Modulated Radiotherapy: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 580450	5.3	2
48	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. <i>BMC Cancer</i> , <b>2020</b> , 20, 901	4.8	2
47	S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1499	5.3	4
46	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. <i>BMC Cancer</i> , <b>2020</b> , 20, 877	4.8	1
45	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. <i>BMC Cancer</i> , <b>2020</b> , 20, 278	4.8	2
44	Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , <b>2019</b> , 108, 1701-1709	2.7	9
43	Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy. <i>BMC Cancer</i> , <b>2019</b> , 19, 478	4.8	10
42	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. <i>Radiation Oncology</i> , <b>2019</b> , 14, 106	4.2	10
41	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. <i>Journal of Cancer</i> , <b>2019</b> , 10, 1985-1990	4.5	6
40	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 2890-2898	3.1	14

39	A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. <i>BMC Cancer</i> , <b>2019</b> , 19, 397	4.8	10
38	Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1431-1440	3.2	9
37	Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. <i>Oncogene</i> , <b>2019</b> , 38, 4990-5006	9.2	43
36	A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. <i>Radiation Oncology</i> , <b>2019</b> , 14, 48	4.2	15
35	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 140, 159-166	5.3	10
34	Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma. <i>Scientific Reports</i> , <b>2019</b> , 9, 10497	4.9	3
33	ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 802-803	3.1	
32	Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 799-806	3.2	2
31	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1918070	10.4	7
30	Small cell lung cancer in the young: Characteristics, diagnosis and outcome data. <i>Clinical Respiratory Journal</i> , <b>2019</b> , 13, 98-104	1.7	2
29	Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis. <i>Translational Oncology</i> , <b>2018</b> , 11, 999-1006	4.9	16
28	Inhibition of survivin enhances radiosensitivity of esophageal cancer cells by switching radiation-induced senescence to apoptosis. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 3087-3100	4.4	10
27	The Impact of Postoperative Conformal Radiotherapy After Radical Surgery on Survival and Recurrence in Pathologic T3N0M0 Esophageal Carcinoma: A Propensity Score-Matched Analysis. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1143-1151	8.9	23
26	Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. <i>Cancer Science</i> , <b>2017</b> , 108, 590-597	6.9	27
25	A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 104, 1718-1724	2.7	15
24	Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 763-771	4.4	34
23	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. <i>Oncotarget</i> , <b>2017</b> , 8, 41102-41112	3.3	8
22	The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC). <i>Oncotarget</i> , <b>2017</b> , 8, 48922-48929	3.3	6

21	Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy. <i>Oncologist</i> , <b>2016</b> , 21, 1530-1537	5.7	22
20	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy. <i>Oncotarget</i> , <b>2016</b> , 7, 55211-55221	3.3	11
19	A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1565-73	8.9	20
18	Postoperative intensity-modulated radiotherapy improved survival in lymph node-positive or stage III thoracic esophageal squamous cell carcinoma. <i>Oncology Research and Treatment</i> , <b>2015</b> , 38, 97-102	2.8	28
17	Associations of ATM Polymorphisms With Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Receiving Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 181-9	4	4
16	Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 346-53	3.2	17
15	Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 399-406	3.2	16
14	Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 597-604	3.2	14
13	Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy. <i>Radiation Oncology</i> , <b>2015</b> , 10, 142	4.2	10
12	Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma. <i>Annals of Thoracic Surgery</i> , <b>2014</b> , 98, 513-9	2.7	39
11	Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 330-7	4	36
10	Prognosis of esophageal squamous cell carcinoma patients with preoperative radiotherapy: Comparison of different cancer staging systems. <i>Thoracic Cancer</i> , <b>2014</b> , 5, 204-10	3.2	7
9	Prognosis of R1-resection at the bronchial stump in patients with non-small cell lung cancer. <i>Chinese Medical Journal</i> , <b>2014</b> , 127, 2918-23	2.9	2
8	Small proline-rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage-induced apoptosis. <i>Molecular Oncology</i> , <b>2013</b> , 7, 955-67	7.9	10
7	Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma. <i>World Journal of Surgical Oncology</i> , <b>2013</b> , 11, 278	3.4	30
6	High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. <i>Tumor Biology</i> , <b>2011</b> , 32, 1147-53	2.9	28
5	Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution. <i>Oncologist</i> , <b>2011</b> , 16, 641-50	5.7	55
4	Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 488-94	5.3	62

3	PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. <i>Cancer Research</i> , <b>2009</b> , 69, 3283-90	10.1	39
2	Primary small cell carcinoma of the esophagus. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 1460-5	8.9	70
1	Radiotherapy for carcinoma of the Esophagus: Progress of treatment and research in China. <i>Chinese Journal of Clinical Oncology</i> , <b>2006</b> , 3, 305-314		1